-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

What’s Different about Atypical Chronic Myeloid Leukemia and Chronic Neutrophilic Leukemia?

Program: Education Program
Session: Managing Typical and Atypical Chronic Myeloid Leukemia
Saturday, December 5, 2015, 9:30 AM-11:00 AM
Valencia BC (W415BC), Level 4 (Orange County Convention Center)
Sunday, December 6, 2015, 7:30 AM-9:00 AM
W224, Level 2 (Orange County Convention Center)

Kim-Hien T. Dao, DO, PhD

Knight Cancer Institute, Oregon Health and Science University, Portland, OR

Disclosures: Dao: Incyte Corporation: Research Funding . Off Label Use: Ruxolitinib. Clinical trial investigation of safety and efficacy in aCML and CNL..

See more of: Managing Typical and Atypical Chronic Myeloid Leukemia
See more of: Education Program
<< Previous Presentation | Next Presentation